MA55200A - Composés utiles dans la thérapie du vih - Google Patents

Composés utiles dans la thérapie du vih

Info

Publication number
MA55200A
MA55200A MA055200A MA55200A MA55200A MA 55200 A MA55200 A MA 55200A MA 055200 A MA055200 A MA 055200A MA 55200 A MA55200 A MA 55200A MA 55200 A MA55200 A MA 55200A
Authority
MA
Morocco
Prior art keywords
useful compounds
hiv therapy
hiv
therapy
compounds
Prior art date
Application number
MA055200A
Other languages
English (en)
Inventor
La Rosa Martha Alicia De
John F Miller
B Narasimhulu Naidu
Vicente Samano
David Temelkoff
Emile Johann Velthuisen
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55200(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Viiv Healthcare Co filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA55200A publication Critical patent/MA55200A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
MA055200A 2019-03-06 2020-03-04 Composés utiles dans la thérapie du vih MA55200A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06

Publications (1)

Publication Number Publication Date
MA55200A true MA55200A (fr) 2022-01-12

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055200A MA55200A (fr) 2019-03-06 2020-03-04 Composés utiles dans la thérapie du vih

Country Status (22)

Country Link
US (4) US12240853B2 (fr)
EP (1) EP3934760A1 (fr)
JP (1) JP2022525013A (fr)
KR (1) KR20210136052A (fr)
CN (1) CN113811360A (fr)
AR (1) AR118240A1 (fr)
AU (1) AU2020231934B2 (fr)
BR (1) BR112021017604A2 (fr)
CA (1) CA3132112A1 (fr)
CL (1) CL2021002309A1 (fr)
CO (1) CO2021012579A2 (fr)
CR (1) CR20210460A (fr)
EA (1) EA202192433A1 (fr)
IL (1) IL285894A (fr)
MA (1) MA55200A (fr)
MX (1) MX2021010700A (fr)
PE (1) PE20212089A1 (fr)
PH (1) PH12021500034A1 (fr)
SG (1) SG11202109253SA (fr)
TW (1) TW202102233A (fr)
WO (1) WO2020178767A1 (fr)
ZA (1) ZA202106096B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022000965A2 (pt) * 2019-07-27 2022-06-14 Brii Biosciences Inc Derivado de adenosina e composição farmacêutica que compreende o mesmo
EP4028020A4 (fr) 2019-09-11 2023-09-27 The Scripps Research Institute Promédicaments antiviraux et formulations de ceux-ci
CN114786648A (zh) 2019-12-09 2022-07-22 Viiv保健公司 包含卡博特韦的药物组合物
AR121620A1 (es) * 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
CN117964624A (zh) * 2020-12-30 2024-05-03 南方科技大学 一种具有治疗病毒感染功效的核苷类化合物及其用途
CN116801884B (zh) 2021-01-25 2026-02-27 腾盛博药生物科技有限公司 使用腺苷衍生物和衣壳抑制剂的针对hiv的组合疗法
CA3202049A1 (fr) * 2021-01-25 2022-07-28 Brii Biosciences, Inc. Derive d'adenosine et composition pharmaceutique le comprenant
JP2024507550A (ja) * 2021-02-23 2024-02-20 ヴィーブ、ヘルスケア、カンパニー Ｈｉｖ療法に有用な化合物
KR20250140092A (ko) * 2023-01-30 2025-09-24 머크 샤프 앤드 돔 엘엘씨 4'-치환된 뉴클레오시드 리버스 트랜스크립타제 억제제의 전구약물
WO2025068912A1 (fr) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Compositions pharmaceutiques
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE60005501T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-pyrimidine nukleoside
NZ528270A (en) 2001-03-19 2005-10-28 Ono Pharmaceutical Co Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CA2502109C (fr) 2004-03-24 2010-02-23 Yamasa Corporation Derive de 2-haloadenosine avec substitution sur le carbone en position 4'
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2011005860A2 (fr) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. Mimétiques de 5' phosphate
WO2011100131A2 (fr) 2010-01-28 2011-08-18 Alnylam Pharmacuticals, Inc. Monomères et oligonucléotides comprenant un ou plusieurs adduits de cycloaddition
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
US9770035B2 (en) 2011-10-06 2017-09-26 Dow Agrosciences Llc Nucleic acid molecules that target RPA70 and confer resistance to coleopteran pests
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN104203253A (zh) 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (fr) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
EP3203995A4 (fr) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska Compositions et méthodes d'administration d'agents thérapeutiques
WO2016066283A1 (fr) * 2014-10-31 2016-05-06 Sandoz Ag Procédé de fluoration amélioré
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
KR102185996B1 (ko) * 2015-09-23 2020-12-02 머크 샤프 앤드 돔 코포레이션 4'-치환된 뉴클레오시드 리버스 트랜스크립타제 억제제 및 그의 제조법
JOP20170038B1 (ar) 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
ES3035041T3 (en) 2016-06-23 2025-08-27 Viiv Healthcare Co Compositions and methods for the delivery of therapeutics
WO2018085307A1 (fr) 2016-11-03 2018-05-11 Wu Laurence I Promédicaments de clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
JP2021515771A (ja) * 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ療法に有用な化合物
TWI863903B (zh) 2018-04-09 2024-12-01 日商衛材R&D企管股份有限公司 特定普拉二烯內酯化合物及其使用方法
US20220117993A1 (en) 2018-08-09 2022-04-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
US20210323993A1 (en) 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
JP7565293B2 (ja) 2019-03-06 2024-10-10 グリーンテック・グローバル・プライベート・リミテッド ハロゲン化アシルのための液体分散体

Also Published As

Publication number Publication date
US20230174534A1 (en) 2023-06-08
AR118240A1 (es) 2021-09-22
BR112021017604A2 (pt) 2021-11-16
TW202102233A (zh) 2021-01-16
CO2021012579A2 (es) 2021-10-20
MX2021010700A (es) 2021-10-01
AU2020231934A8 (en) 2022-03-24
AU2020231934A1 (en) 2021-09-23
SG11202109253SA (en) 2021-09-29
JP2022525013A (ja) 2022-05-11
PE20212089A1 (es) 2021-11-04
EA202192433A1 (ru) 2021-12-28
US12240853B2 (en) 2025-03-04
CL2021002309A1 (es) 2022-09-20
PH12021500034A1 (en) 2022-06-06
IL285894A (en) 2021-10-31
US20220411425A1 (en) 2022-12-29
ZA202106096B (en) 2023-03-29
EP3934760A1 (fr) 2022-01-12
CN113811360A (zh) 2021-12-17
KR20210136052A (ko) 2021-11-16
US20260035371A1 (en) 2026-02-05
US20240182473A1 (en) 2024-06-06
CR20210460A (es) 2022-02-03
WO2020178767A1 (fr) 2020-09-10
AU2020231934B2 (en) 2023-04-20
CA3132112A1 (fr) 2020-09-10

Similar Documents

Publication Publication Date Title
MA55200A (fr) Composés utiles dans la thérapie du vih
MA53280A (fr) Composés utiles dans la thérapie du vih
EP4045442A4 (fr) Dépalettiseur robotisé assisté par vision
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
EP3915928A4 (fr) Grue
EP3989959A4 (fr) Formulations transdermiques
EP4003475A4 (fr) Interface patient
EP3999156A4 (fr) Interface patient
EP3359100A4 (fr) Utilisation d'un manchon stérile dans la production d'une bouillie chirurgicale
EP4043002A4 (fr) Composition dentaire
EP3946535A4 (fr) Interface patient
EP3849570A4 (fr) Compositions contenant du plasma sanguin
EP4032455A4 (fr) Dispositif de nettoyage
EP3952625A4 (fr) Convertisseur
EP4037681C0 (fr) Forme posologique de gel masticable
EP3980440A4 (fr) Agents anti-inflammatoires
EP4029491A4 (fr) Composition dentaire polymérisable
EP3960060A4 (fr) Dispositif de nettoyage
EP3941217A4 (fr) Composition épaississante
EP3924140C0 (fr) Portique d'équilibrage de poids
DK3722239T3 (da) Elevator
IL288237A (en) Combination therapy
EP3949952A4 (fr) Composition médicinale
EP4061375A4 (fr) Agents antipaludiques
PL3996650T3 (pl) Wanna